BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34464167)

  • 1. Low Expression of KAT6B May Affect Prognosis in Hepatocellular Carcinoma.
    Jiang J; Wang HJ; Mou XZ; Zhang H; Chen Y; Hu ZM
    Technol Cancer Res Treat; 2021; 20():15330338211033063. PubMed ID: 34464167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
    Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
    BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
    Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
    Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma.
    Chen Y; Yang S; Hu J; Yu C; He M; Cai Z
    PLoS One; 2016; 11(5):e0154939. PubMed ID: 27183310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of PTH1R is a poor prognosis in hepatocellular carcinoma.
    Wang HJ; Wang L; Song SS; He XL; Pan HY; Hu ZM; Mou XZ
    Cancer Biomark; 2018 Feb; 21(3):723-730. PubMed ID: 29278884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma.
    Tsai MC; Huang CC; Wei YC; Liu TT; Lin MT; Yi LN; Lin PR; Wang CC; Chu TH; Hsiao CC; Hu TH; Tai MH
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression Pattern and Clinical Significance of Gab2 Protein in Hepatocellular Carcinoma.
    Hu X; He B; Zhou L; Xie H; Zheng S
    Clin Lab; 2016; 62(6):1087-92. PubMed ID: 27544933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival.
    Guo X; Xiong L; Zou L; Sun T; Zhang J; Li H; Peng R; Zhao J
    Diagn Pathol; 2012 Aug; 7():96. PubMed ID: 22888955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma.
    Cai L; Cai X
    Diagn Pathol; 2014 Dec; 9():1000. PubMed ID: 25552204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
    Liu T; Chen J; Xiao S; Lei X
    Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis.
    Shi XM; Teng F
    Int J Clin Exp Pathol; 2015; 8(4):4008-14. PubMed ID: 26097588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
    Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
    J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.
    Gu Y; Li X; Bi Y; Zheng Y; Wang J; Li X; Huang Z; Chen L; Huang Y; Huang Y
    Aging (Albany NY); 2020 Jan; 12(1):784-807. PubMed ID: 31927532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role and reduced expression of FOXJ2 in human hepatocellular carcinoma.
    Zhang Z; Meng G; Wang L; Ma Y; Guan Z
    Mol Med Rep; 2016 Jul; 14(1):254-62. PubMed ID: 27177166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL-mediated extrinsic signaling pathway.
    Xu S; Shu P; Zou S; Shen X; Qu Y; Zhang Y; Sun K; Zhang J
    Cancer Med; 2018 Sep; 7(9):4701-4717. PubMed ID: 30085405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma.
    Zhou L; Jin Y; Cui QC; Jin KM; Zhou WX; Xing BC
    World J Surg; 2013 Mar; 37(3):608-13. PubMed ID: 23188538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
    Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
    World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.